Back to discover
Drug

Retatrutide

Late-stage clinical development
ClassGlucagon-like peptide 1 receptor agonist
RxNorm2722410ChEMBLCHEMBL5095485UNIINOP2Y096GV
11
Active clinical trials
3
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Retatrutide Tops Ozempic for Weight Loss, A1c in T2D

Industry2026-10-30Medscape Medical News

Retatrutide reduces osteoarthritis pain in patients with obesity

Industry2026-10-29Healio Orthopedics

Lilly’s retatrutide beats Ozempic in head-to-head trial

Clinical trial2026-10-28Trial news · Clinical Trials Arena

Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes

Industry2026-10-28Endpoints News

Retatrutide cost in 2026: What a research vial really costs and why the cheapest listing is a red flag

Research2026-10-27Research news · Clinical Trials Arena

Lilly’s retatrutide creeps closer to market for sleep apnea

Industry2026-10-21Endpoints News

1 in 4 Army Men Have Low T; GLP-1 in Menopause; Retatrutide Side Effects on Reddit

Industry2026-10-20MedPage Today

Could Retatrutide Break a GLP-1 Weight-Loss Plateau?

Industry2026-10-20Medscape Medical News

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes

Clinical trial2026-10-08Results expected Q3 2030 · ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

Clinical trial2026-10-08Results expected Q1 2029 · ClinicalTrials.gov

A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Clinical trial2026-08-27Primary completion · ClinicalTrials.gov

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial

Clinical trial2026-07-30Status changed to Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Retatrutide
RxNorm CUI
2722410
ChEMBL ID
CHEMBL5095485
UNII
NOP2Y096GV
Primary mechanism
Glucagon-like peptide 1 receptor agonist

Pharmacology & targets

3 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Glucagon-like peptide 1 receptor
GLP1R · P43220
AGONISTGlucagon-like peptide 1 receptor agonist
Glucagon receptor
GCGR · P47871
AGONISTGlucagon receptor agonist
Gastric inhibitory polypeptide receptor
GIPR · P48546
AGONISTGastric inhibitory polypeptide receptor agonist

Clinical trials

19 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
19
registered trials across all phases
LATEST COMPLETION 2026
11
Active studies
2
Recruiting
14
Late-stage (III+)
8
Completed
PHASE DISTRIBUTIONn = 19
Phase 13Phase 22Phase 314

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes

RecruitingPH IIIKey trialEli Lilly and Companyn=4,5002032

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

Active, not recruitingPH IIIKey trialEli Lilly and Companyn=10,0002029

A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial

Active, not recruitingPH IIIEli Lilly and Companyn=6002028

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity

Active, not recruitingPH IIIEli Lilly and Companyn=6432028

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Active, not recruitingPH IIIEli Lilly and Companyn=5862027

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial

CompletedPH IIIKey trialEli Lilly and Companyn=1,1522026

A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease

CompletedPH IIIKey trialEli Lilly and Companyn=1,9462026

A Randomized, Placebo-Controlled, Parallel Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia

CompletedPH IEli Lilly and Companyn=802026

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)

CompletedPH IIIKey trialEli Lilly and Companyn=2,3352026

A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

CompletedPH IIIEli Lilly and Companyn=5372026

A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial

CompletedPH IIIEli Lilly and Companyn=4452025
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials